Clinical stage biotech Apitope has appointed Dr William Jenkins as its independent, non-executive director to its board.
Dr Jenkins has a wealth of pharmaceutical industry experience following a 30-year career in clinical medicine and research.
He has also served on several boards including Ablynx, Evotec and Acambis.
Stéphane Verdood, chairman of the board, said: “We are pleased to welcome William to Apitope’s board of directors.
“William’s extensive drug development expertise is a valuable addition as we seek to advance development of our potential first-in-class antigen-specific treatments targeted at autoimmune diseases.
“William has advised companies through various stages of growth to maturity and I know he will provide further strength and depth to the board.”